4.5 Article

Amplification of chromosomal segment 4q12 in non-small cell lung cancer

Journal

CANCER BIOLOGY & THERAPY
Volume 8, Issue 21, Pages 2042-2050

Publisher

TAYLOR & FRANCIS INC
DOI: 10.4161/cbt.8.21.9764

Keywords

NSCLC; lung cancer; PDGFRA; KIT; sunitinib; imatinib; amplification; 4q12

Categories

Funding

  1. Swiss National Science Foundation [PBZHB- 106297]
  2. National Cancer Institute [5R01CA109038, 5P20CA90578]

Ask authors/readers for more resources

In cancer, proto-oncogenes are often altered by genomic amplification. Here we report recurrent focal amplifications of chromosomal segment 4q12 overlapping the proto-oncogenes PDGFRA and KIT in non-small cell lung cancer (NSCSCLC). Single nucleotide polymorphism (SNP) array and fluorescent in situ hybridization (FISH) analysis indicate that 4q12 is amplified in 3-7% of lung adenocarcinomas and 8-10% of lung squamous cell carcinomas. In addition, we demonstrate that the NSCLC cell line NCI-H1703 exhibits focal amplification of PDGFRA and is dependent on PDGFR alpha activity for cell growth. Treatment of NCI-H1703 cells with PDGFRA-specific shRNAs or with the PDGFR alpha/KIT small molecule inhibitors imatinib or sunitinib leads to cell growth inhibition. However, these observations do not extend to NSCLC cell lines with lower-amplitude and broader gains of chromosome 4q. Together these observations implicate PDGFRA and KIT as potential oncogenes in NSCLC, but further study is needed to define the specific characteristics of those tumors that could respond to PDGFR alpha/KIT inhibitors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available